Dr. Schultz, former Chief Scientific Officer and Global Head of R&D for Merial, joins the KindredBio team.
SAN FRANCISCO, California. (July 2, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today that it has appointed Kevin Schultz, DVM, PhD, former Chief Scientific Officer and Head of R&D for Merial, as Chief Scientific Officer and Head of R&D for KindredBio.
Dr. Schultz has developed dozens of products over his career, including Frontline Plus®, a blockbuster flea and tick medication with over a billion dollars in annual sales, Oncept®, a skin cancer vaccine for dogs, Previcox®, a pain medicine for dogs, and Gastrogard®, an anti-ulcer drug for horses. Dr. Schultz started his career at Merck, and subsequently served as the Head of R&D at Merial, which is one of the largest veterinary pharmaceutical companies in the world. He trained in immunology, oncology, and dermatology, and served as Professor at the University of Wisconsin before joining Merck.
Richard Chin, CEO of KindredBio, stated, “We’re very pleased to welcome Kevin to the KindredBio team. He is one of the most accomplished drug developers in the veterinary industry, with an unmatched track record, and he will be a tremendous addition as we move forward with our mission of helping companion animals in need.”
Kevin Schultz stated, “I am excited to join KindredBio with its promising pipeline and a new approach to developing drugs for companion animals. KindredBio is poised for tremendous success and I am looking forward to working with the team as we continue to advance the drugs in the portfolio.”
“Best Medicines for Our Best Friends”
KindredBio is a leading veterinary biotechnology company, focused on developing breakthrough therapies for dogs, cats, and horses. Founded by industry veterans formerly from Genentech and Elan Pharmaceuticals who have experience developing antibody drugs such as Lucentis®, Tysabri®, Xolair®, and Rituxan®, Kindred Bio is committed to bringing the very best science and medicine to companion animals.
Forward-looking statements in this news release involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in such forward-looking statements. These factors include, but are not limited to uncertainties associated with: drug development and regulatory review process, scientific discovery process, competition, pricing environment, financing, intellectual property, and evolution of the companion animal market. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date.
Lucentis® is a registered trademarks of Genentech, Inc. Rituxan® is a registered trademark of Biogen Idec Inc. Xolair® is a registered trademark of Novartis AG Corporation. Tysabri® is a trademark of Elan Pharmaceuticals, Inc. Oncept®, Previcox®, and Gastrogard® are registered trademarks of Merial.